In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1888 News Items found
Andi Straus and her son, Nadav, pose on a hiking trail.
Targeted Therapy Shows Promising Results Against Rare Soft Tissue Sarcoma

A clinical trial led by doctors from MSK has found that abemaciclib — a drug already approved for certain breast cancers — can significantly slow the growth of dedifferentiated liposarcoma, a rare, aggressive soft tissue cancer.
MSK radiation oncologist Nancy Lee
In the Clinic
Low-Dose Radiation Successfully Treats HPV Throat Cancer With Fewer Side Effects

Learn how HPV-related head and neck cancer can be treated with a sharply reduced radiation dose to prevent side effects, sometimes without surgery.
MSK breast cancer specialist Pedram Razavi, MD, PhD.
Article
Latest Research Into Overcoming Resistance to Breast Cancer Targeted Therapies

Learn how MSK's researchers are making important strides in overcoming breast cancer resistance.
An MSK researcher at work in the lab
MSK Research Highlights, May 26, 2026

New MSK research provides structural insights into how cancer cells thwart targeted RAS therapies; uncovers promising combination therapies for a rare childhood brain tumor; uses organoids to provide important clues about what drives pancreatic cancer; takes aim at appendix cancer with new laboratory models; and a develops a new precision tool for targeting cancer's energy factory.
Dr. Shanu Modi speaks with a patient
In the Clinic
FDA Approves Trastuzumab Deruxtecan (T-DXd) for Early-Stage HER2-Positive Breast Cancer

The FDA has approved trastuzumab deruxtecan (T-DXd, Enhertu) for treating early-stage, HER2-positive breast cancer based in part on clinical research led by MSK breast medical oncologist Shanu Modi, MD.
Dr. Alison Schram
FDA Approves Zenocutuzumab for Cholangiocarcinoma Based on MSK-Led Trial

The FDA has approved zenocutuzumab (Bizengri®) for adults with advanced, unresectable, or metastatic cholangiocarcinoma driven by a molecular change called an NRG1 gene fusion, based on a trial led by an MSK investigator.
Riders on stationary bikes cheer and hold pompoms in a party-like atmosphere for Cycle for Survival
MSK Giving in 2025

In 2025, the MSK Giving community accelerated its commitment to redefine what’s possible in cancer care worldwide. Together, 348,000 donors contributed...
GSK Graduates and MSK Leadership pose on the stage
MSK’s 2026 Graduation Recognizes Today's Achievements and Tomorrow's Leaders

At Memorial Sloan Kettering Cancer Center’s 47th annual ceremony, graduating master's and PhD students were honored and award winners were recognized.
A doctor holds the hand of a patient, who is dressed in a hospital gown
Just Diagnosed With a Brain Tumor? What You Should Do Next

Learn what to do right after you've been diagnosed with brain cancer, from MSK experts who specialize in treating this kind of cancer.
micrograph of a T cell
Successfully Treated AML Patients May Hold the Key to New CAR T Cell Therapy

A team of researchers from MSK has developed a new type of CAR T cell therapy that shows promise against acute myeloid leukemia (AML) in preclinical models.